Stay updated with breaking news from Thrombus. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A large, modern real-world analysis published today in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI), provides vital insights into the safety of novel therapies including ultrasound-assisted catheter-directed thrombolysis (USCDT) and mechanical thrombectomy (MT) that have been developed to address the increased morbidity and mortality of elevated risk pulmonary embolism (PE). Findings were presented today at TCT 2023. ....
The quest for an anticoagulant that can prevent cardiovascular events without bleeding is something of a holy grail in cardiovascular medicine. Could factor XI inhibitors be the long-sought answer? ....
An approach that involves stratifying patients by thrombosis risk reduced the incidence of thromboembolism and death among high-risk individuals with lung and GI cancers. ....
The phase 2 AZALEA-TIMI 71 trial in AF shows "an overwhelming reduction" in major and clinically relevant nonmajor bleeding with investigational Factor XI inhibitor abelacimab vs rivaroxaban. ....